Report cover image

Total Artificial Heart Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update

Publisher GlobalData
Published Apr 29, 2024
Length 72 Pages
SKU # GBDT18798851

Description

Total Artificial Heart Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update


Summary

GlobalData's Medical Devices sector report, “Total Artificial Heart Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the Total Artificial Heart pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

A Total Artificial Heart is a prosthetic device that is implanted into the body to replace the biological heart.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Total Artificial Heart under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Total Artificial Heart and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Total Artificial Heart under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents

72 Pages
  • About GlobalData
    • Total Artificial Heart Overview
    • Total Artificial Heart - Pipeline Products by Stage of Development
    • Total Artificial Heart - Pipeline Products by Territory
    • Total Artificial Heart - Pipeline Products by Regulatory Path
    • Total Artificial Heart - Pipeline Products by Estimated Approval Date
    • Total Artificial Heart - Ongoing Clinical Trials
    • Total Artificial Heart Companies - Pipeline Products by Stage of Development
    • Total Artificial Heart - Companies Pipeline Products by Stage of Development
    • Abiomed Inc Company Overview
    • Aerospace Taixin Technology Co Ltd Company Overview
    • BioLife4D Corp Company Overview
    • BiVacor Pty Ltd Company Overview
    • Carmat SAS Company Overview
    • Cleveland Clinic Lerner College of Medicine Company Overview
    • Cleveland Heart Inc Company Overview
    • Collplant Biotechnologies Ltd Company Overview
    • CoRISMA MCS Systems Inc Company Overview
    • Foster-Miller Inc (Inactive) Company Overview
    • Griffith University Company Overview
    • Lausanne University Hospital Company Overview
    • OregonHeart Inc (Inactive) Company Overview
    • ReliantHeart, Inc. Company Overview
    • Scandinavian Real Heart AB Company Overview
    • Shanghai Xinhengrui Medical Technology Co Ltd Company Overview
    • Suzhou Xinqing Medical Technology Co Ltd Company Overview
    • Syncardia Systems LLC Company Overview
    • University of New South Wales Company Overview
    • University of Tokyo Company Overview
    • Feb 20, 2024: Revolutionary Artificial Heart a Lifeline for Heart Failure Patients
    • Feb 20, 2024: BiVACOR Receives $13 Million to Support Clinical Trials for the Company's Total Artificial Heart
    • Feb 06, 2024: Realheart Appoints Andreas Hultdin as Interim CFO Following the Resignation of Jonas Caspari Bark
    • Feb 05, 2024: Syncardia Systems Announces Publication of Patent Application Covering Innovative Total Artificial Heart Design
    • Jan 15, 2024: CARMAT Achieves a Pivotal Year in 2023 by Reaching the Milestone of 50 Implants of the Aeson Artificial Heart and Presents Its Development Prospects
    • Dec 28, 2023: Carmat Announces a Software Enhancement which Significantly Improves the Safety Profile of its Aeson Artificial Heart
    • Dec 27, 2023: BiVacor Names Axonics CEO as Chair of its Board
    • Dec 11, 2023: Carmat Announces the First Implant of the Aeson Artificial Heart in a Patient Suffering from a Cardiac Tumor
    • Nov 30, 2023: BiVACOR wins IDE to start first-in-human study for artificial heart
    • Nov 29, 2023: magAssist Attended 2023 ISMCS to Showcase its Next-Gen Medical Solutions that Improve Treatment Outcomes of Critical Heart Diseases
    • Nov 21, 2023: National Heart Centre Singapore partners Mede
    • Nov 16, 2023: Scandinavian Real Heart: Interim Report July to September 2023
    • Nov 13, 2023: Realheart Provides an Update on the Development and Commercialization of Its Artificial Heart
    • Nov 01, 2023: Realheart has Successfully Established a Novel Test System to Evaluate Hemolysis of its Total Artificial Heart
    • Sep 25, 2023: CARMAT Reports its 2023 Half-Year Results and Provides an Update on its Strategic Progress
    • Sep 05, 2023: First Patient With Nyokassist Interventional Ventricular Assist Device: Dr. Junbo Ge's Team Successfully Completed the First High-Risk PCI Treatment Supported by the New Generation of Interventional VAD
    • Aug 30, 2023: Stuart McConchie Appointed Adjunct Board Member to Realheart
    • Aug 24, 2023: Scandinavian Real Heart Announces Interim Report 2023
    • Aug 23, 2023: Realheart's CEO to Speak at China Heart Congress
    • Aug 22, 2023: magAssist's ventricular pump scores FDA breakthrough designation
    • Aug 10, 2023: Magnus Ohman Appointed Adjunct Board Member to Realheart
    • Jul 11, 2023: SynCardia Updates Total Artificial Heart Labeling with Real World Data
    • Jun 28, 2023: Realheart Gets Go-Ahead for International Trademark Protection
    • Jun 15, 2023: Cardiac Surgeon Dilek Gursoy Speaks About Realheart's Artificial Heart at Impact LECH
    • Jun 14, 2023: Scandinavian Real Heart Announces Bulletin from the Annual General Meeting held on 14 June 2023
    • Jun 08, 2023: Realheart Part of Vinnova Project for Cordless TAH Technology
    • May 24, 2023: Realheart Releases the Annual Report for 2022
    • May 03, 2023: Scientists at Scandinavian Real Heart and at the University of Bath Publish the World's First Computer Simulation Method for Dual Mechanical Heart Valves in Series
    • Methodology
    • About GlobalData
    • Contact Us
    • Disclaimer

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us